Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial

Status Completed

Clinical Trial Summary

Excessive menstrual loss (menorrhagia) is a common condition that affects women of reproductive age, and can result in anemia, chronic fatigue and lost wages from work. The traditional first line management involves treatment with oral contraceptives or non-steroidal anti-inflammatory agents. Many women ultimately undergo hysterectomy, a major operative procedure associated with increased costs, loss of feeling of womanhood, debilitating complications and on rare occasions, death.

The newer global endometrial ablation (GEA) devices allow the destruction of the endometrial lining, without the removal of the uterus, in an ambulatory surgery setting. GEA offers a safe and effective alternative to hysterectomy with minimal risks and without unpleasant side-effects.

Presently, global endometrial ablation is offered as an alternative to hysterectomy, after medical intervention has failed. This study will determine the role of global endometrial ablation in the initial management of menorrhagia. Women seeking treatment for menorrhagia will be randomized to either the medical treatment arm or the global endometrial ablation arm.

This study will be the first to compare clinical efficacy and costs between oral contraceptive pills and global endometrial ablation in the initial management of menorrhagia and could potentially change the management of menorrhagia and impact millions of women who suffer from this condition.

Clinical Trial Description

Goal of study: To evaluate the safety, effectiveness as well as cost- effectiveness of Global Endometrial Ablation (GEA) as an initial treatment for menorrhagia.

Specific aim #1: To determine if global endometrial ablation (GEA) is more effective than medical therapy in the initial management of menorrhagia.

Specific aim #2: To determine disease-specific resource utilization and costs associated with the treatment alternatives and the cost effectiveness of global endometrial ablation (GEA) compared with medical treatment (oral contraceptive pills) in the initial management of menorrhagia. ;

Study Design

Related Conditions & MeSH terms

Menorrhagia

Clinical Trial Details

NCT number	NCT01165307
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Completed
Phase	Phase 4
Start date	August 2009
Completion date	October 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02824224` - Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)	Phase 4
Withdrawn	`NCT01651468` - The Effect of the Nutraceutical "Hemofix" on the Coagulation System	N/A
Recruiting	`NCT02616731` - Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD	Phase 1/Phase 2
Terminated	`NCT02087228` - Evaluation of the Endometrial Cavity After Endometrial Ablation	N/A
Withdrawn	`NCT00953641` - Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy	Phase 3
Completed	`NCT01436903` - Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length	Phase 4
Withdrawn	`NCT00768742` - Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study	N/A
Completed	`NCT00156195` - Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids	Phase 3
Completed	`NCT00152256` - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids	Phase 3
Completed	`NCT00160381` - A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids	Phase 3
Completed	`NCT02228174` - Sonography Guided Transcervical Ablation of Uterine Fibroids	N/A
Terminated	`NCT01969396` - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology	N/A
Completed	`NCT00386308` - Efficacy and Safety Study of XP12B in Women With Menorrhagia	Phase 3
Completed	`NCT00393198` - Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia	Phase 4
Completed	`NCT00966264` - Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia	Phase 3
Completed	`NCT00904709` - The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders	Phase 4
Recruiting	`NCT03670680` - Efficiency of Lina LibrataTM System	N/A
Completed	`NCT02584088` - Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation
Completed	`NCT02835391` - PerClot Compared to Usual Care in Gynaecology Procedures	N/A
Completed	`NCT02304510` - Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia — iTOM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms